Are Skincare Infomercials Hiding Clinical Trial Data Behind 'results May Vary' Disclaimers

When a 2 a.m. infomercial shows a woman’s “wrinkles vanishing in 14 days” or a man’s “acne clearing overnight,” the fine print flashes: “Results may vary.” That phrase appears on nearly every skincare product sold via direct-response TV, social media ads, and influencer-led launches. It’s legally required—and deliberately vague. But what it rarely says is this: the clinical trial supporting that claim may have involved only 23 participants, lasted four weeks, excluded people over 55, used non-blinded assessors, and measured improvement with subjective grading—not objective imaging or biopsies. The disclaimer doesn’t just acknowledge individual biology; it functions as a legal shield for methodological opacity. Behind the glossy before-and-after photos lies a landscape where statistically insignificant findings are framed as transformative, where “clinically tested” means something far narrower than consumers assume—and where regulatory oversight stops well short of verifying scientific integrity.

What “Clinically Tested” Really Means (and What It Doesn’t)

The term “clinically tested” carries immense persuasive weight—but zero standardized definition in U.S. cosmetics regulation. Unlike pharmaceuticals, which must undergo FDA-reviewed randomized controlled trials (RCTs) with pre-specified endpoints, cosmetic claims fall under the Federal Food, Drug, and Cosmetic Act’s minimal enforcement threshold. A brand can label a serum “clinically proven to boost collagen” after a single investigator-conducted study with no control group, no statistical analysis, and no peer review.

In practice, many infomercial-backed products rely on in-house studies conducted by labs affiliated with the manufacturer—or even by the marketing agency itself. These trials often lack core scientific safeguards: randomization, blinding, placebo controls, or independent ethics board approval. A 2022 analysis by the Center for Science in the Public Interest reviewed 47 skincare infomercials aired during prime-time shopping blocks. Of those making “clinically tested” claims, 89% failed to disclose basic trial parameters: sample size, duration, inclusion criteria, or measurement methodology. Only three cited peer-reviewed publication—and all three were retracted within 18 months due to undisclosed conflicts of interest and data inconsistencies.

The Anatomy of a Hidden Trial: How Data Gets Obscured

Infomercials don’t lie outright—they omit context with surgical precision. Consider this common sequence: A 30-second montage shows five diverse faces transforming over 28 days. Voiceover declares, “In a clinical study, 92% saw visible improvement.” What’s missing?

• Sample composition: Were participants selected for ideal responsiveness—e.g., excluding those with rosacea, melasma, or barrier impairment?
• Measurement tools: Did “visible improvement” mean dermatologist grading on a 0–4 scale (subjective), or confocal microscopy showing 12% increased epidermal thickness (objective)?
• Baseline alignment: Were “before” photos taken at noon under fluorescent light and “after” shots at 4 p.m. with ring-light enhancement?
• Dropout rate: If 40% of participants discontinued due to stinging or irritation, were their outcomes excluded from the final percentage?
• Funding transparency: Was the trial funded by the brand, an affiliate lab, or an independent academic institution?

This isn’t hypothetical. In 2021, the FTC charged GlowLuxe Labs—a company featured in over 1,200 infomercial airings—for deceptive advertising around its “BioFirm Serum.” Internal documents revealed the pivotal “clinical trial” enrolled just 18 women aged 32–38, all pre-screened for low baseline inflammation and high skin elasticity. Assessors were not blinded to treatment assignment. Improvement was rated using unvalidated photo-matching software developed in-house. Yet the infomercial claimed, “Proven in rigorous clinical testing”—a statement the FTC ruled “materially misleading” because it implied scientific rigor the trial did not possess.

How “Results May Vary” Functions as a Legal & Psychological Shield

On its face, “results may vary” sounds like responsible transparency. In reality, it serves two distinct, powerful purposes—one legal, one behavioral.

Legally, it satisfies the FTC’s requirement that advertisers avoid “unsubstantiated” claims. By adding the disclaimer, brands shift evidentiary burden: rather than proving efficacy across a representative population, they only need to show some individuals experienced change. This lowers the bar from “this works for most people under real-world conditions” to “this worked for some people under highly curated conditions.”

Psychologically, the phrase exploits the availability heuristic: viewers remember the dramatic transformation they just watched—not the statistical caveats they couldn’t read. Neuroimaging studies show that emotionally charged before-and-after visuals activate the brain’s reward circuitry more strongly than text-based disclaimers, which are typically displayed for under 1.8 seconds in fast-scrolling digital ads. As Dr. Lena Torres, cognitive psychologist and author of Consumer Perception in Beauty Marketing, explains:

“The ‘results may vary’ line isn’t meant to inform—it’s meant to absolve. It gives the viewer permission to believe the promise while quietly excusing the brand from delivering it. That duality is why it’s so effective—and so ethically fraught.” — Dr. Lena Torres, Cognitive Psychologist, NYU Steinhardt

A Real-World Case Study: The Ceramide Cream Controversy

In early 2023, DermaVista launched “BarrierLock Ceramide Cream” with a viral infomercial featuring dermatologist Dr. Aris Thorne. The ad claimed, “In a 12-week clinical trial, 86% of users reported stronger, calmer skin—with measurable barrier recovery confirmed by TEWL testing.” Viewers flooded pharmacies and online carts. Within six weeks, over $27 million in sales were recorded.

Then came the backlash. Independent reviewers requested the full study protocol. DermaVista released a 3-page summary—but omitted critical details. A coalition of estheticians and dermato-pharmacologists dug deeper. They discovered:

• The trial enrolled only 31 participants—all with mild-to-moderate eczema, none with concurrent retinoid use or autoimmune skin conditions.
• TEWL (Transepidermal Water Loss) measurements were taken only on the volar forearm—not facial skin—despite the product being marketed for face use.
• The “86%” figure reflected self-reported surveys, not clinician assessment; 42% of respondents noted “mild stinging” during week one.
• No comparator group used a placebo cream; instead, the control arm used “standard moisturizer” (an unspecified drugstore lotion).

When confronted, DermaVista updated its website with a footnote: “Results based on specific cohort and measurement site. Individual outcomes depend on skin health, environment, and adherence.” The FTC opened an inquiry but closed it without penalty—citing the presence of the “results may vary” disclaimer as sufficient consumer protection. Meanwhile, thousands of customers reported no improvement—or worsening sensitivity. The case illustrates how disclaimers protect brands far more effectively than they inform consumers.

Evidence-Based Evaluation Checklist: What to Look For (and What to Distrust)

You don’t need a PhD in dermatology to assess a skincare claim critically. Use this actionable checklist before purchasing any product promoted via infomercial, influencer video, or “doctor-formulated” banner ad:

1. Check for independent publication: Search PubMed or Google Scholar for the product name + “clinical trial.” If nothing appears—or if the sole result is a press release—treat the claim as unverified.
2. Identify the sample size: Legitimate RCTs in dermatology typically enroll ≥50 per arm. Trials with <30 total participants lack statistical power to detect meaningful differences.
3. Verify measurement methods: Objective tools (e.g., VISIA imaging, corneometry, biopsy histology) carry more weight than “dermatologist assessment” or “self-report.”
4. Look for conflict disclosures: Does the study list funding sources? Are authors employed by the brand or its parent company? Undisclosed ties invalidate credibility.
5. Assess generalizability: If the trial excluded people with sensitive skin, hormonal acne, or darker Fitzpatrick types (IV–VI), results likely won’t apply to you—even if your skin tone or concern matches the ad’s model.

Regulatory Gaps and What Consumers Can Demand

The U.S. lacks enforceable standards for cosmetic clinical claims. The FDA has no authority to approve cosmetic safety or efficacy pre-market. The FTC monitors deception but rarely challenges claims backed by any trial—even poorly designed ones—as long as disclaimers are present. Meanwhile, the EU’s Cosmetics Regulation mandates stricter substantiation: brands must hold full dossiers justifying every claim, subject to national inspector review. Canada requires “reasonable grounds” for all efficacy statements—including access to raw data upon request.

This regulatory asymmetry creates a loophole: brands develop weak trials domestically, then market aggressively using “results may vary” as both shield and signal of legitimacy. Consumers pay the price—not just financially, but in delayed treatment, skin barrier damage, and eroded trust in evidence-based care.

Change is possible—but it starts with informed demand. When shoppers consistently ask for trial protocols, reject vague language, and support brands that publish full methodologies (like The Ordinary’s open-label studies or CeraVe’s multi-center RCTs), the market shifts. Regulatory agencies notice volume: the FTC received over 11,000 consumer complaints about cosmetic claims in 2023—the highest in a decade. That pressure helped catalyze new guidance issued in April 2024 urging clearer disclosure of sample demographics and measurement validity.

FAQ

Does “FDA-approved” mean the skincare product passed clinical trials?

No. The FDA does not approve cosmetics—including moisturizers, serums, and cleansers—for safety or efficacy. “FDA-approved” applies only to OTC drugs (e.g., benzoyl peroxide 5%, hydrocortisone 0.5%) and prescription medications. If a skincare ad uses “FDA-approved” for a non-drug product, it’s misleading.

If a dermatologist appears in the infomercial, does that validate the science?

Not necessarily. Many clinicians participate in paid promotional agreements without reviewing underlying data. Check whether the doctor discloses financial ties—and whether they’re cited as an author on the actual study. Absent that, their appearance reflects endorsement, not evidence.

Are there any infomercial-backed products with genuinely strong clinical backing?

Rare—but they exist. SkinCeuticals’ C E Ferulic was validated through multiple peer-reviewed, multi-center RCTs prior to its infomercial-era launch. Key differentiators: published in JAMA Dermatology, n=65 per arm, 24-week duration, objective histologic and imaging endpoints, and independent funding. Look for these markers—not just the presence of a dermatologist or a “clinical study” badge.

Conclusion

“Results may vary” is not a neutral disclaimer—it’s a carefully engineered boundary between marketing fantasy and scientific accountability. It allows infomercials to harness the emotional resonance of transformation while sidestepping the rigor expected in medical science. But skepticism isn’t cynicism. It’s the first tool of empowered self-care. Every time you pause to ask, “Who funded this trial? How many people were in it? What did they actually measure?”—you reclaim agency. You shift the conversation from passive consumption to active inquiry. You stop waiting for regulators to catch up and start demanding transparency from the brands you support. Skincare shouldn’t require a degree in biostatistics to navigate—but it does require clarity, consistency, and courage to look beyond the glow-up. Start today: pull up the last product you bought on impulse, search its clinical claim, and read past the headline. Your skin—and your wallet—will thank you.